Fully human antibody against human CD 137
Disclosed are a fully human monoclonal antibody specifically binding to a CD137 or an antigen binding portion thereof. On one hand, provided are a CDR/variable region sequence of the antibody and an encoding nucleic acid sequence thereof; on the other hand, provided is a method for treating diseases using the antibody or the antigen binding portion thereof. a fully human monoclonal antibody specifically binding to a CD137 or an antigen binding portion thereof. On one hand, provided are a CDR/variable region sequence of the antibody and an encoding nucleic acid sequence thereof; on the other hand, provided is a method for treating diseases using the antibody or the antigen binding portion thereof.
1. An antibody specifically binding to CD137 or an antigen-binding portion thereof, comprising a heavy chain variable region and a light chain variable region, wherein:
said heavy chain variable region comprises a CDR1 having a sequence as set forth in SEQ ID NO.5, a CDR2 having a sequence as set forth in SEQ ID NO.6, and a CDR3 having a sequence as set forth in SEQ ID NO.7; and
said light chain variable region comprises a CDR1 having a sequence as set forth in SEQ ID NO.10, a CDR2 having a sequence as set forth in SEQ ID NO.11, and a CDR3 having a sequence as set forth in SEQ ID NO.12;
or
said heavy chain variable region comprises a CDR1 having a sequence as set forth in SEQ ID NO.15, a CDR2 having a sequence as set forth in SEQ ID NO.16, and a CDR3 having a sequence as set forth in SEQ ID NO.17; and
said light chain variable region comprises a CDR1 having a sequence as set forth in SEQ ID NO.20, a CDR2 having a sequence as set forth in SEQ ID NO.21, and a CDR3 having a sequence as set forth in SEQ ID NO.22;
or
said heavy chain variable region comprises a CDR1 having a sequence as set forth in SEQ ID NO.15, a CDR2 having a sequence as set forth in SEQ ID NO.29, and a CDR3 having a sequence as set forth in SEQ ID NO.17; and
said light chain variable region comprises a CDR1 having a sequence as set forth in SEQ ID NO.20, a CDR2 having a sequence as set forth in SEQ ID NO.21, and a CDR3 having a sequence as set forth in SEQ ID NO.22;
or said heavy chain variable region comprises a CDR1 having a sequence as set forth in SEQ ID NO.32, a CDR2 having a sequence as set forth in SEQ ID NO.16, and a CDR3 having a sequence as set forth in SEQ ID NO.17; and
said light chain variable region comprises a CDR1 having a sequence as set forth in SEQ ID NO.20, a CDR2 having a sequence as set forth in SEQ ID NO.21, and a CDR3 having a sequence as set forth in SEQ ID NO.22;
or
said heavy chain variable region comprises a CDR1 having a sequence as set forth in SEQ ID NO.15, a CDR2 having a sequence as set forth in SEQ ID NO.16, and a CDR3 having a sequence as set forth in SEQ ID NO.17; and
said light chain variable region comprises a CDR1 having a sequence as set forth in SEQ ID NO.20, a CDR2 having a sequence as set forth in SEQ ID NO.35, and a CDR3 having a sequence as set forth in SEQ ID NO.22;
or
said heavy chain variable region comprises a CDR1 having a sequence as set forth in SEQ ID NO.15, a CDR2 having a sequence as set forth in SEQ ID NO.16, and a CDR3 having a sequence as set forth in SEQ ID NO.17; and
said light chain variable region comprises a CDR1 having a sequence as set forth in SEQ ID NO.20, a CDR2 having a sequence as set forth in SEQ ID NO.21, and a CDR3 having a sequence as set forth in SEQ ID NO.38;
or
said heavy chain variable region comprises a CDR1 having a sequence as set forth in SEQ ID NO.15, a CDR2 having a sequence as set forth in SEQ ID NO.16, and a CDR3 having a sequence as set forth in SEQ ID NO.17; and
said light chain variable region comprises a CDR1 having a sequence as set forth in SEQ ID NO.20, a CDR2 having a sequence as set forth in SEQ ID NO.21, and a CDR3 having a sequence as set forth in SEQ ID NO.41;
or
said heavy chain variable region comprises a CDR1 having a sequence as set forth in SEQ ID NO.15, a CDR2 having a sequence as set forth in SEQ ID NO.16, and a CDR3 having a sequence as set forth in SEQ ID NO.17; and
said light chain variable region comprises a CDR1 having a sequence as set forth in SEQ ID NO.20, a CDR2 having a sequence as set forth in SEQ ID NO.35, and a CDR3 having a sequence as set forth in SEQ ID NO.41.
2. The antibody or an antigen-binding portion thereof according to claim 1 , wherein:
said heavy chain comprises a variable region having a sequence as set forth in SEQ ID NO.4; and
said light chain comprises a variable region having a sequence as set forth in SEQ ID NO.9;
or
said heavy chain comprises a variable region having a sequence as set forth in SEQ ID NO.14; and
said light chain comprises a variable region having a sequence as set forth in SEQ ID NO.19;
or
said heavy chain comprises a variable region having a sequence as set forth in SEQ ID NO.28; and
said light chain comprises a variable region having a sequence as set forth in SEQ ID NO.19;
or
said heavy chain comprises a variable region having a sequence as set forth in SEQ ID NO.31; and
said light chain comprises a variable region having a sequence as set forth in SEQ ID NO.19;
or
said heavy chain comprises a variable region having a sequence as set forth in SEQ ID NO.14; and
said light chain comprises a variable region having a sequence as set forth in SEQ ID NO.34;
or
said heavy chain comprises a variable region having a sequence as set forth in SEQ ID NO.14; and
said light chain comprises a variable region having a sequence as set forth in SEQ ID NO.37;
or
said heavy chain comprises a variable region having a sequence as set forth in SEQ ID NO.14; and
said light chain comprises a variable region having a sequence as set forth in SEQ ID NO.40;
or
said heavy chain comprises a variable region having a sequence as set forth in SEQ ID NO.14; and
said light chain comprises a variable region having a sequence as set forth in SEQ ID NO.43.
3. The antibody or an antigen-binding portion thereof according to claim 1 , wherein said antibody or said antigen-binding portion thereof is a complete antibody, a bispecific antibody, scFv, Fab, Fab′, F(ab) 2 or Fv.
4. A single-chain antibody, comprising a VH, a VL and a linker peptide, wherein the VH has a sequence as set forth in SEQ ID NO.4, the VL has a sequence as set forth in SEQ ID NO.9, and the linker peptide has a sequence as set forth in SEQ ID NO.1 or the VH has a sequence as set forth in SEQ ID NO.14, the VL has a sequence as set forth in SEQ ID NO.19 and the linker peptide has a sequence as set forth in SEQ ID NO.1.
5. A pharmaceutical composition, comprising:
the antibody or an antigen-binding portion thereof of claim 1 ; and
a pharmaceutically acceptable carrier.
6. An isolated polynucleotide, comprising a nucleotide sequence encoding an amino acid sequence as set forth in SEQ ID NO.4, SEQ ID NO.14, SEQ ID NO.28, SEQ ID NO.31.
7. The polynucleotide according to claim 6 , comprising a nucleotide sequence as set forth in SEQ ID NO.8, SEQ ID NO.18, SEQ ID NO.30, or SEQ ID NO.33.
8. An isolated polynucleotide, comprising a nucleotide sequence encoding an amino acid sequence as set forth in SEQ ID NO.9, SEQ ID NO.19, SEQ ID NO.34, SEQ ID NO.37, SEQ ID NO.40, or SEQ ID NO.43.
9. The polynucleotide according to claim 8 , comprising a nucleotide sequence as set forth in SEQ ID NO.13, SEQ ID NO.23, SEQ ID NO.36, SEQ ID NO.39, SEQ ID NO.42, or SEQ ID NO.44.
10. A vector, containing a nucleotide sequence as set forth in SEQ ID NO.8, SEQ ID NO.18, SEQ ID NO. 30, or SEQ ID NO.33.
11. A vector, containing a nucleotide sequence as set forth in SEQ ID NO.13, SEQ ID NO.23, SEQ ID NO.36, SEQ ID NO.39, SEQ ID NO.42, or SEQ ID NO.44.
12. A cell, containing a nucleotide sequence as set forth in SEQ ID NO.8, SEQ ID NO.18, SEQ ID NO.30, or SEQ ID NO.33.
13. A cell, containing a nucleotide sequence as set forth in SEQ ID NO.13, SEQ ID NO.23, SEQ ID NO.36, SEQ ID NO.39, SEQ ID NO.42, or SEQ ID NO.44.